Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23753187 | 0.98 | KMT2A (0.50) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| SCHEMBL1467259 | 0.88 | KEAP1 (0.50) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6622428 | 0.86 | KEAP1 (0.48) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL6623533 | 0.84 | KEAP1 (0.47) | KMT2AMEN1GLAKEAP1SMN1; SMN2 | |
| SCHEMBL28572354 | 0.82 | MEN1 (0.55) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| SCHEMBL29993988 | 0.79 | HRH3 (0.40) | KMT2AALDH1A1SMN1; SMN2MAPTHRH3 | |
| SCHEMBL426048 | 0.78 | MEN1 (0.51) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| SCHEMBL4974769 | 0.78 | MEN1 (0.51) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| SCHEMBL18770758 | 0.78 | KMT2A (0.51) | KMT2AMEN1GLAKDM4EALDH1A1 | |
| SCHEMBL426047 | 0.78 | KMT2A (0.51) | KMT2AMEN1GLAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545669-B2 | Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2026-02-10 | — | — | US | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220251075-A1 | Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| US-20210253598-A1 | ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| EP-3710447-A1 | ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| EP-1996580-B1 | PYRRAZOLE DERIVATIVES AS SIGMA RECEPTORS ANTAGONISTS | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| CN-101638383-B | Quinoline as well as pharmaceutical composition and use thereof | UNIV PEKING FOUNDER GROUP CO | 2013-07-10 | — | — | CN | disclosed |
| US-8138186-B2 | Pyrazole derivatives as sigma receptors antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-03-20 | — | — | US | disclosed |
| EP-1874739-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| WO-2007098964-A2 | PYRRAZOLE DERIVATIVES AS SIGMA RECEPTORS ANTAGONISTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| EP-1829873-A1 | Pyrrazole derivatives as sigma receptors antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006111371-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2006-10-26 | — | — | WO | disclosed |
| CN-1264824-C | Quinazoline derivatives | MITSUBISHI PHARMA CORP (JP) | 2006-07-19 | — | — | CN | disclosed |
| US-20040116422-A1 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| CN-1492860-A | Quinazoline derivatives | ������ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1369418-A1 | QUINAZOLINE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251075-A1 | Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives | BRIX1, CCNA1, RB1 | KMT2A 980/4885MEN1 1605/4885GLA 4279/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | KMT2A 4775/4885MEN1 2496/4885GLA 3891/4885 |
| US-12545669-B2 | Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives | NHERF1, CBX8, BCL9 | KMT2A 82/4885MEN1 1756/4885GLA 4639/4885 |
| US-20210253598-A1 | ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES | AHR, IDO1, CCNA1 | KMT2A 755/4885MEN1 335/4885GLA 3149/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | KMT2A 3039/4885MEN1 2014/4885GLA 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.